BeyondSpring Stock Quote BYSI - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

2.29

Bid

2.20

Ask

2.50

Volume

0.00 Day's Range 0.00

0.6534 52 Week Range 4.00

Market Cap

87.181M

Previous Close

2.29

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

237,777

Shares Outstanding

38,920,000

Dividend Yield

PE Ratio

-2.62

Earnings Per Share (EPS)

-0.86

Revenue

1.35M

Net Profit

-33.28M

BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities... BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.beyondspringpharma.com

Headquarters

New York, New York, USA

Founded

1970

BeyondSpring Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BYSI. The last closing price for BeyondSpring was $2.29. Over the last year, BeyondSpring shares have traded in a share price range of $ 0.6534 to $ 4.00.

BeyondSpring currently has 38,920,000 shares outstanding. The market capitalization of BeyondSpring is $87.18 million. BeyondSpring has a price to earnings ratio (PE ratio) of -2.62.

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.49	27.2222222222	1.8	2.379	1.79	83202	2.01322281	CS
4	-1.36	-37.2602739726	3.65	3.69	1.76	105062	2.6116228	CS
12	1.2902	129.045809162	0.9998	4	0.97	237777	2.77360565	CS
26	1.26	122.330097087	1.03	4	0.7777	135623	2.43240791	CS
52	1.24	118.095238095	1.05	4	0.6534	98889	1.99331631	CS
156	-7.94	-77.61485826	10.23	33	0.542	671905	13.33809172	CS
260	-12.25	-84.250343879	14.54	33	0.542	457687	13.30461551	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AAGRAfrican Agriculture Holdings Inc	$ 0.35 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 61.09 (0.00%)	0
AADIAadi Bioscience Inc	$ 1.84 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 11.27 (0.00%)	0
AACGATA Creativity Global	$ 0.8906 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.35 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 61.09 (0.00%)	0
AADIAadi Bioscience Inc	$ 1.84 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 11.27 (0.00%)	0
AACGATA Creativity Global	$ 0.8906 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.35 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 61.09 (0.00%)	0
AADIAadi Bioscience Inc	$ 1.84 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 11.27 (0.00%)	0
AACGATA Creativity Global	$ 0.8906 (0.00%)	0